Abstracts
8 June 2009
Vol. 2 No. 5 (2006)
https://doi.org/10.4081/hmr.v2i5.383

Frequency and characteristics of hematologic and non-hematologic Bortezomib-related toxicity

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
218
Views
1707
Downloads

Authors

Marzia Varettoni
support@pagepress.org
ortezomib (Velcade®) is the first of a new class of drugs known as proteasome-inhibitors. Its efficacy has been established in phase II trials SUMMIT and CREST and phase III trial APEX has demonstrated the superiority of Bortezomib (Velcade®) over high-dose dexamethasone in relapsed/refractory multiple myeloma (MM) patients. Although generally well tolerated, several side-effects are correlated to the administration of Bortezomib (Velcade®).

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Frequency and characteristics of hematologic and non-hematologic Bortezomib-related toxicity. (2009). Hematology Meeting Reports, 2(5). https://doi.org/10.4081/hmr.v2i5.383